Kantar Health Blog

  • Stephanie Hawthorne
    Oncology Conference Insight: ECC 2015 --- Without a doubt, PD-1 and PD-L1 inhibitors have taken the oncology field by storm. With its approval in Japan in July 2014 for unresectable melanoma, Opdivo® (nivolumab, Bristol-Myers Squibb/Ono Pharmaceuticals) was the first PD-1 inhibitor to be approved worldwide and represented the culmination of a longstanding quest to harness the body’s inherent immune system to combat cancer.
    Continue Reading > | Go comment! | Share
  • Arnold DuBell
    Oncology Conference Insight: ECC 2015 --- Sutent® (sunitinib, Pfizer) and Votrient® (pazopanib, Novartis) are currently considered the standards of care for first-line therapy in renal cell carcinoma (RCC). However, neither drug (nor any other agents currently approved) has been able to show an overall survival (OS) benefit in clinical trials; they were approved by regulatory agencies based on a significant improvement in progression-free survival (PFS).
    Continue Reading > | Go comment! | Share
  • Bladder Cancer Treatment IMvigor-ated

    by Stephanie Hawthorne | Sep 28, 2015
    Stephanie Hawthorne
    Oncology Conference Insight: ECC 2015 --- Approximately 70% to 80% of patients with newly diagnosed bladder cancer will present with superficial or Stage I bladder tumors. Patients with these superficial tumors can often be cured, but those with muscle-invasive or metastatic disease are cured less often and are treated with surgery, irradiation or a combination of modalities that includes systemic therapy.
    Continue Reading > | Go comment! | Share
  • Mark Sales
    Everything our son interacts with seems to be connected to In the Night Garden. The branding and messaging are so tightly controlled to deliver the same experience through each channel. So, what has this got to do with Pharma?
    Continue Reading > | Go comment! | Share
  • Debbie Warner
    Opdivo (nivolumab, Bristol-Myers Squibb) is approved for the treatment of patients with squamous cell non-small cell lung cancer (NSCLC) who have relapsed on platinum-based chemotherapy. Based on the clinical trial that served as the basis for approval, Opdivo did not stratify response rates based on PD-L1 levels, and the approved label does not have a biomarker requirement.
    Continue Reading > | Go comment! | Share